Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7220263 | 0.75 | QPCT (0.37) | CYP19A1CYP17A1 | |
| SCHEMBL7216865 | 0.72 | ACHE (0.43) | KCNH2KMT2AMEN1MAPK1 | |
| SCHEMBL7570570 | 0.71 | ALDH1A1 (0.50) | KMT2AALDH1A1POLBMEN1 | |
| SCHEMBL7216749 | 0.70 | LOXL2 (0.38) | CYP19A1 | |
| SCHEMBL7216927 | 0.69 | KDM4E (0.49) | KCNH2ALDH1A1MITFMAPK1 | |
| SCHEMBL7214446 | 0.69 | NPC1 (0.38) | KMT2AALDH1A1POLBMEN1MAPK1 | |
| SCHEMBL7220974 | 0.68 | DPP4 (0.38) | CYP19A1CYP17A1 | |
| SCHEMBL7221098 | 0.68 | TAAR1 (0.39) | KCNH2KMT2AMEN1CYP17A1 | |
| SCHEMBL7220444 | 0.68 | PRCP (0.41) | — | |
| SCHEMBL7221460 | 0.67 | KMT2A (0.40) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6630485-B2 | For therapy of inflammatory disease | SYNTEX (U.S.A.) LLC | 2003-10-07 | — | — | US | disclosed |
| US-6479507-B2 | MODULATION OF THESE INFLAMMATORY CYTOKINES IS CONSIDERED ONE OF THE MOST EFFECTIVE STRATEGIES TO BLOCK CHRONIC INFLAMMATION AND HAVE POSITIVE THERAPEUTIC OUTCOMES | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-6316464-B1 | P38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |